Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   489 Trials   489 Trials   8953 News 


«12...2425262728293031323334...123124»
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab (Exhibition area) -  Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_751;    
    Moreover, patients in metformin group had significantly shorter PFS compared to patients in no-metformin group [respectively, 4.5 months (95% CI 2.9-14.2) vs. 5.8 (95% CI 4.1-34.0); HR 1.6 (95% CI 1.0-2.6) p = 0.0212], as confirmed in multivariate analysis (HR 1.7; 95% CI, 1.1-2.7; p=0.0147).No statistically significant differences in terms of both OS and PFS were found between patients in metformin group and patients in no-metformin group in Lenvatinib arm. Conclusions The present study reports the first analysis focused on the role of metformin in a large double cohort of patients affected by advanced HCC who received Lenvatinib or Atezolizumab plus Bevacizumab, thus showing a negative prognostic role of metformin use in the Atezolizumab plus Bevacizumab group.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab (Exhibition area) -  Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_728;    
    At the univariate analysis for OS, no significative difference was found between normal-weight versus underweight and between normal-weight versus overweight, which was confirmed at multivariate analysis. Conclusions Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in the lenvatinib arm.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Efficacy of low dose nivolumab in recurrent / metastatic cervical cancer (Hall 401) -  Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_381;    
    Conclusions In patients with R/M cervical cancer, Low dose Nivolumab is effective with manageable toxicity. It can help reduce financial toxicity and make it accessible to more patients especially in low- and middle-income countries where the burden of this disease is higher.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial termination, Trial primary completion date, Checkpoint inhibition:  Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors (clinicaltrials.gov) -  Oct 5, 2023   
    P=N/A,  N=17, Terminated, 
    It reproduced the effects of a therapeutic agent (lenvatinib) previously used in preclinical AAA studies, therefore extending our understanding of its therapeutic effect through a multicellular structure. Trial completion date: Feb 2023 --> Sep 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Sep 2023; The sponsor withdrawed the sponsorship to the study.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jemperli (dostarlimab-gxly) / GSK, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Immuno-oncology:  Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens. (Pubmed Central) -  Oct 4, 2023   
    Now there is approval for use of dostarlimab in frontline chemotherapy and maintenance for advanced stage or recurrent endometrial cancer. Several upcoming trials investigating molecular subgroups from the TCGA are eagerly anticipated.
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy. (Pubmed Central) -  Oct 4, 2023   
    Vascular endothelial growth factor tyrosine kinase inhibitors (TKI), such as sunitinib, and mammalian target of rapamycin (mTOR) inhibitors, such as everolimus, have demonstrated efficacy and remain viable treatment options, with a preference for sunitinib...Clinically meaningful antitumor activity has been observed across all non-clear cell histologies for immune checkpoint inhibitors, such as nivolumab, pembrolizumab, and ipilimumab. Ongoing trials are evaluating novel tyrosine kinase inhibitor and immunotherapy combination regimens, with an emphasis on the promising MET-inhibitor cabozantinib and pembrolizumab plus lenvatinib.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jemperli (dostarlimab-gxly) / GSK, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Checkpoint inhibition, Metastases:  Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. (Pubmed Central) -  Oct 2, 2023   
    In 2022, 85.7% of the centers already administrated the pembrolizumab plus lenvatinib combination as a second-line therapy for MMR-proficient (pMMR) patients with advanced or recurrent EC who had progressed from first-line platinum-based therapy. Both the therapeutic and diagnostic scenarios have changed over the last couple of years in MITO centers, with an increased prescription of immune checkpoint inhibitors and use of the molecular classification.
  • ||||||||||  rocapuldencel-T (CMN-001) / CoImmune, SCM Lifescience
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Oct 2, 2023   
    P2b,  N=16, Terminated, 
    Both the therapeutic and diagnostic scenarios have changed over the last couple of years in MITO centers, with an increased prescription of immune checkpoint inhibitors and use of the molecular classification. N=120 --> 16 | Trial completion date: Mar 2024 --> Sep 2023 | Recruiting --> Terminated | Trial primary completion date: Mar 2024 --> Sep 2023; Strategic corporate decision
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    NFAT5 deficiency correlates with features of carcinogenesis in anaplastic thyroid carcinoma in-vitro (Hall A) -  Sep 30, 2023 - Abstract #DGHO2023DGHO_974;    
    Of interest, the cytotoxicity of doxorubicin could be improved by co-incubation with the TKI Lenvatinib in NFAT5-deficient NthyOri3-1 cells. Our investigations suggest that NFAT5 expression is worsened in ATC and that NFAT5 deficiency is stronger associated with prognostic negative characteristics in-vitro .
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Paraneoplastic Psoriasis in Thymic Carcinoma: A Case Report (X2) -  Sep 30, 2023 - Abstract #DGHO2023DGHO_676;    
    Ten months later, he was diagnosed with thymic carcinoma (Masaoka-Koga stage IVb). The tumor initially responded well to treatment with PAC and irradiation.
  • ||||||||||  Journal:  Therapeutic inhibition of ATR in differentiated thyroid cancer. (Pubmed Central) -  Sep 30, 2023   
    No appreciable toxicity appeared in animals treated with either a single therapy or combination treatment. Our findings provide the rationale for the development of clinical trials of BAY 1895344 in the treatment of DTC.
  • ||||||||||  Review, Journal, Surgery:  Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy. (Pubmed Central) -  Sep 29, 2023   
    Lenvatinib and atezolizumab plus bevacizumab showed marginal effects...In addition, adequate adjuvant therapies with hepatic arterial chemotherapy and transarterial chemoembolization may be beneficial but an effective adjuvant molecular therapy is currently unavailable. In conclusion, novel molecular therapies with higher response rates customized to the oncologic characteristics of each hepatocellular carcinoma with macroscopic vascular invasion are needed to increase the likelihood of conversion surgery and improve long-term outcomes.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jemperli (dostarlimab-gxly) / GSK, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, Checkpoint inhibition, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases:  Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis. (Pubmed Central) -  Sep 28, 2023   
    Pembrolizumab/dostarlimab have been approved for MMRd ECs, with the addition of lenvatinib for MMRp cases in the recurrent setting. Future efforts will focus on the pathological assessment of biomarkers to determine molecular phenotypes that correlate with response or resistance to ICI in order to identify patients most likely to benefit from this treatment.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Nivolumab plus ipilimumab in anti-PD(L)-1 na (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1214;    
    Future efforts will focus on the pathological assessment of biomarkers to determine molecular phenotypes that correlate with response or resistance to ICI in order to identify patients most likely to benefit from this treatment. Among those who received prior targeted therapy, sorafenib, lenvatinib, and regorafenib were administered in 34...7% (10/23) of patients had prior anti-PD(L)-1 treatment, with nivolumab, pembrolizumab, atezolizumab + bevacizumab, and durvalumab administered in 47...Conclusions Nivolumab combined with ipilimumab demonstrated greater effectiveness in anti-PD(L)-1 na
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed:  NeoLeap-HCC: Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Sep 21, 2023   
    P2,  N=43, Active, not recruiting, 
    Therefore, the combined therapy has the potential to become a treatment option for advanced CCA. Recruiting --> Active, not recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    NOW YOU SEE ME, NOW YOU DON'T: COMPLETE RESOLUTION OF A SUSPICIOUS THYROID NODULE AFTER IMMUNOTHERAPY FOR UTERINE CANCER () -  Sep 20, 2023 - Abstract #ATA2023ATA_680;    
    The patient is a female in her mid?50s with stage IVB uterine serous carcinoma who underwent oncologic resection then carboplatin and paclitaxel therapy followed by bevacizumab, but had progression of disease...She was intermittently on levothyroxine during this time for hypothyroidism...Pembrolizumab is known to cause adverse effects on the thyroid, including hypothyroidism. It is unclear which, if either, of these immunotherapies were responsible for complete resolution of the suspicious nodule or could have any treatment potential in the future for malignant thyroid nodules.